NASDAQ:ASND - Ascendis Pharma A/S Stock Price, Price Target & More Sign in or create an account to add this stock to your watchlist. Get Started $69.18 -1.67 (-2.36 %) (As of 07/23/2018 03:49 AM ET)Previous Close$69.18Today's Range$68.58 - $71.6252-Week Range$26.30 - $76.29Volume114,686 shsAverage Volume134,139 shsMarket Capitalization$2.87 billionP/E Ratio-15.98Dividend YieldN/ABeta0.7 Company ProfileFinancialsAnalyst RatingsEarnings HistoryHeadlinesOptions ChainSEC FilingsSocial MediaChart Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Ascendis Pharma A/S, a clinical stage biopharmaceutical company, develops various prodrug therapies for unmet medical needs. The company develops TransCon human growth hormone, which is in Phase III clinical study in children to treat growth hormone deficiency; TransCon parathyroid hormone that is in Phase I clinical study for treating hypoparathyroidism; and TransCon C-type natriuretic peptide for the treatment of achondroplasia. It also has strategic collaborations with Sanofi to develop TransCon Peptides for the treatment of diabetes; and Genentech and Roche to develop TransCon anti-vascular endothelial growth factor (VEGF), a compound to support injection of anti-VEGF in ophthalmology. Ascendis Pharma A/S was founded in 2006 and is headquartered in Hellerup, Denmark. Receive ASND News and Ratings via Email Sign-up to receive the latest news and ratings for ASND and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical SymbolNASDAQ:ASND CUSIPN/A Webwww.ascendispharma.com Phone45-7022-2244 Debt Debt-to-Equity RatioN/A Current Ratio20.55 Quick Ratio20.55 Price-To-Earnings Trailing P/E Ratio-15.98 Forward P/E Ratio-15.87 P/E GrowthN/A Sales & Book Value Annual Sales$1.80 million Price / Sales1,595.75 Cash FlowN/A Price / CashN/A Book Value$5.82 per share Price / Book11.89 Profitability EPS (Most Recent Fiscal Year)($4.33) Net Income$-140,040,000.00 Net Margins-12,089.94% Return on Equity-64.87% Return on Assets-59.63% Miscellaneous Employees137 Outstanding Shares41,520,000Market Cap$2,872.63 Ascendis Pharma A/S (NASDAQ:ASND) Frequently Asked Questions What is Ascendis Pharma A/S's stock symbol? Ascendis Pharma A/S trades on the NASDAQ under the ticker symbol "ASND." How were Ascendis Pharma A/S's earnings last quarter? Ascendis Pharma A/S (NASDAQ:ASND) posted its quarterly earnings results on Wednesday, May, 30th. The biotechnology company reported ($1.31) earnings per share for the quarter, missing the consensus estimate of ($0.93) by $0.38. The biotechnology company had revenue of $0.03 million for the quarter, compared to analyst estimates of $0.30 million. Ascendis Pharma A/S had a negative net margin of 12,089.94% and a negative return on equity of 64.87%. View Ascendis Pharma A/S's Earnings History. When is Ascendis Pharma A/S's next earnings date? Ascendis Pharma A/S is scheduled to release their next quarterly earnings announcement on Friday, August, 17th 2018. View Earnings Estimates for Ascendis Pharma A/S. What price target have analysts set for ASND? 8 analysts have issued twelve-month price objectives for Ascendis Pharma A/S's stock. Their predictions range from $51.00 to $85.00. On average, they anticipate Ascendis Pharma A/S's stock price to reach $70.7143 in the next year. This suggests a possible upside of 2.2% from the stock's current price. View Analyst Ratings for Ascendis Pharma A/S. What is the consensus analysts' recommendation for Ascendis Pharma A/S? 8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ascendis Pharma A/S in the last year. There are currently 1 hold rating and 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." Who are some of Ascendis Pharma A/S's key competitors? Some companies that are related to Ascendis Pharma A/S include Alnylam Pharmaceuticals (ALNY), Jazz Pharmaceuticals (JAZZ), Genmab A/S (GNMSF), Perrigo (PRGO), Beigene (BGNE), Sarepta Therapeutics (SRPT), Nektar Therapeutics (NKTR), Valeant Pharmaceuticals (VRX), SAGE Therapeutics (SAGE), Alkermes (ALKS), Catalent (CTLT), Ionis Pharmaceuticals (IONS), GALAPAGOS NV/S (GLPG), United Therapeutics (UTHR) and FibroGen (FGEN). Who are Ascendis Pharma A/S's key executives? Ascendis Pharma A/S's management team includes the folowing people: Mr. Michael Wolff Jensen L.L.M., Chairman, Sr. VP, Gen. Counsel and Member of Exec. Board (Age 47)Mr. Jan Møller Mikkelsen, Chief Exec. Officer, Pres, Member of Exec. Board and Exec. Director (Age 58)Mr. Scott T. Smith, Sr. VP & CFO (Age 44)Mrs. Lotte Sønderbjerg, Chief Admin. Officer, Sr. VP and Member of Exec. Board (Age 57)Dr. Grethe Rasmussen Ph.D., Sr. VP of Product Devel. and Member of Exec. Board (Age 56) When did Ascendis Pharma A/S IPO? (ASND) raised $85 million in an initial public offering on Wednesday, January 28th 2015. The company issued 5,000,000 shares at $16.00-$18.00 per share. BofA Merrill Lynch and Leerink Partners acted as the underwriters for the IPO and Wells Fargo Securities was co-manager. Has Ascendis Pharma A/S been receiving favorable news coverage? News coverage about ASND stock has been trending somewhat positive on Monday, according to Accern Sentiment Analysis. The research group ranks the sentiment of media coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Ascendis Pharma A/S earned a coverage optimism score of 0.12 on Accern's scale. They also assigned news articles about the biotechnology company an impact score of 46.30 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the next few days. Who are Ascendis Pharma A/S's major shareholders? Ascendis Pharma A/S's stock is owned by a variety of of retail and institutional investors. Top institutional investors include Matisse Capital (0.03%) and Atria Investments LLC (0.01%). View Institutional Ownership Trends for Ascendis Pharma A/S. Which institutional investors are buying Ascendis Pharma A/S stock? ASND stock was purchased by a variety of institutional investors in the last quarter, including Matisse Capital and Atria Investments LLC. View Insider Buying and Selling for Ascendis Pharma A/S. How do I buy shares of Ascendis Pharma A/S? Shares of ASND can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Ascendis Pharma A/S's stock price today? One share of ASND stock can currently be purchased for approximately $69.18. How big of a company is Ascendis Pharma A/S? Ascendis Pharma A/S has a market capitalization of $2.87 billion and generates $1.80 million in revenue each year. The biotechnology company earns $-140,040,000.00 in net income (profit) each year or ($4.33) on an earnings per share basis. Ascendis Pharma A/S employs 137 workers across the globe. How can I contact Ascendis Pharma A/S? Ascendis Pharma A/S's mailing address is TUBORG BOULEVARD 5, HELLERUP G7, 2900. The biotechnology company can be reached via phone at 45-7022-2244 or via email at [email protected] MarketBeat Community Rating for Ascendis Pharma A/S (NASDAQ ASND)Community Ranking: 2.6 out of 5 ( )Outperform Votes: 165 (Vote Outperform)Underperform Votes: 155 (Vote Underperform)Total Votes: 320MarketBeat's community ratings are surveys of what our community members think about Ascendis Pharma A/S and other stocks. Vote "Outperform" if you believe ASND will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ASND will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 7/23/2018 by MarketBeat.com StaffFeatured Article: Should you buy a closed-end mutual fund?